Molecular Partners (MLLCF) Stock Price, News & Analysis

Company Overview

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Zurich, Switzerland, specializing in the development of novel protein therapeutics based on its proprietary DARPin® (Designed Ankyrin Repeat Proteins) platform. The company’s pipeline focuses on precision molecules engineered for oncology and immuno-inflammatory diseases, as well as antiviral and anti-infective applications. By leveraging the modular nature of DARPin® science, Molecular Partners designs small, highly stable binding proteins that can engage multiple targets simultaneously, potentially improving efficacy and safety profiles over conventional antibody approaches.

Founded in 2004 by Professor Andreas Plückthun at the University of Zurich, Molecular Partners has advanced several clinical-stage candidates through Phase 1 and Phase 2 trials. The company’s oncology portfolio includes bispecific and multispecific DARPins targeting tumor-associated antigens and the immune microenvironment. In addition, Molecular Partners has partnered with large biopharmaceutical firms to develop antiviral therapies, notably advancing treatments for viral infections such as SARS-CoV-2 during the COVID-19 pandemic.

Operating from research facilities in Zurich and a corporate office in Zug, Molecular Partners serves global markets through research collaborations and licensing agreements. Its leadership team is comprised of experienced biotechnology executives, with CEO Janique Godking at the helm since late 2020. Under her guidance, the company continues to expand its pipeline and explore strategic partnerships aimed at accelerating clinical development and commercialization of its DARPin® therapeutics.

Key Stats

• Today's Range: $4.85 to $4.85
• 50-Day Range: $2.33 to $4.85
• 52-Week Range: $2.25 to $4.85
• Volume: N/A
• Average Volume: 831 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/20/2026
• Next Earnings (Estimated): 8/25/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MLLCF
• CIK: N/A
• Web: www.molecularpartners.com
• Phone: (144) 755-7700
• Fax: N/A
• Employees: 167
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A